{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:11:01Z","timestamp":1778775061903,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":3885,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s13311-012-0159-0","type":"journal-article","created":{"date-parts":[[2012,11,26]],"date-time":"2012-11-26T13:59:45Z","timestamp":1353938385000},"page":"29-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Alemtuzumab Therapy for Multiple Sclerosis"],"prefix":"10.1016","volume":"10","author":[{"given":"Alasdair J.","family":"Coles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-012-0159-0_bib1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/332323a0","article-title":"Reshaping human antibodies for therapy","volume":"332","author":"Riechmann","year":"1988","journal-title":"Nature"},{"key":"10.1007\/s13311-012-0159-0_bib2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"10.1007\/s13311-012-0159-0_bib3","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1098\/rstb.2005.1702","article-title":"CAMPATH: from concept to clinic","volume":"360","author":"Waldmann","year":"2005","journal-title":"Phil Trans Roy Soc Lond B Biol Sci"},{"key":"10.1007\/s13311-012-0159-0_bib4","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","article-title":"Remission induction in Behcet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H","volume":"42","author":"Lockwood","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-012-0159-0_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/bjo.84.1.107","article-title":"Campath-1H therapy in refractory ocular inflammatory disease","volume":"84","author":"Dick","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"10.1007\/s13311-012-0159-0_bib6","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1136\/bjo.79.11.1054","article-title":"Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H","volume":"79","author":"Isaacs","year":"1995","journal-title":"Br J Ophthalmol"},{"key":"10.1007\/s13311-012-0159-0_bib7","first-page":"1103","article-title":"Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H","volume":"23","author":"Isaacs","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1007\/s13311-012-0159-0_bib8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/rheumatology\/35.3.231","article-title":"CAMPATH-1H in rheumatoid arthritis \u2014 an intravenous dose-ranging study","volume":"35","author":"Isaacs","year":"1996","journal-title":"Br J Rheumatol"},{"issue":"pt 5","key":"10.1007\/s13311-012-0159-0_bib9","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/eye.1995.140","article-title":"Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody. CAMPATH-1H","volume":"9","author":"Newman","year":"1995","journal-title":"Eye (Lond)"},{"key":"10.1007\/s13311-012-0159-0_bib10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/146532401753174098","article-title":"The CD52 antigen and development of the CAMPATH antibodies","volume":"3","author":"Hale","year":"2001","journal-title":"Cytotherapy"},{"issue":"pt 3","key":"10.1007\/s13311-012-0159-0_bib11","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1042\/bj2930633","article-title":"Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis","volume":"293","author":"Xia","year":"1993","journal-title":"Biochem J"},{"key":"10.1007\/s13311-012-0159-0_bib12","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/eji.1830210714","article-title":"Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone","volume":"21","author":"Xia","year":"1991","journal-title":"Eur J Immunol"},{"key":"10.1007\/s13311-012-0159-0_bib13","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2567.2009.03115.x","article-title":"Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model","author":"Hu","year":"2009","journal-title":"Immunology"},{"key":"10.1007\/s13311-012-0159-0_bib14","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1172\/JCI119110","article-title":"Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a\/CD18 (LFA-1) on NK cells","volume":"98","author":"Wing","year":"1996","journal-title":"J Clin Invest"},{"issue":"pt 1","key":"10.1007\/s13311-012-0159-0_bib15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/brain\/119.1.225","article-title":"Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis","volume":"119","author":"Moreau","year":"1996","journal-title":"Brain"},{"key":"10.1007\/s13311-012-0159-0_bib16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","article-title":"Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis","volume":"83","author":"Hill-Cawthorne","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-012-0159-0_bib17","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1002\/eji.200535075","article-title":"Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis","volume":"35","author":"Cox","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1007\/s13311-012-0159-0_bib18","first-page":"99","article-title":"B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis","author":"Thompson","year":"2009","journal-title":"J Clin Immunol"},{"key":"10.1007\/s13311-012-0159-0_bib19","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple-sclerosis \u2014 an Expanded Disability Status Scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1007\/s13311-012-0159-0_bib20","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#","article-title":"Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis","volume":"46","author":"Coles","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-012-0159-0_bib21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s00415-005-0934-5","article-title":"The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy","volume":"253","author":"Coles","year":"2006","journal-title":"J Neurol"},{"key":"10.1007\/s13311-012-0159-0_bib22","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0b013e31824e8ee7","article-title":"Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 Clinical Trial","author":"Coles","year":"2012","journal-title":"Neurology"},{"key":"10.1007\/s13311-012-0159-0_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s12020-010-9405-6","article-title":"Prevalence of incidental thyroid cancer and its ultrasonographic features in subcentimeter thyroid nodules of patients with hyperthyroidism","volume":"39","author":"Berker","year":"2011","journal-title":"Endocrine"},{"key":"10.1007\/s13311-012-0159-0_bib24","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4049\/jimmunol.1000422","article-title":"A novel strategy to reduce the immunogenicity of biological therapies","volume":"185","author":"Somerfield","year":"2010","journal-title":"J Immunol"},{"key":"10.1007\/s13311-012-0159-0_bib25","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1056\/NEJMc0800484","article-title":"Anti-glomerular basement membrane disease after alemtuzumab","volume":"359","author":"Clatworthy","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-012-0159-0_bib26","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/sj.bmt.1703291","article-title":"Relapse of Graves' disease after successful allogeneic bone marrow transplantation","volume":"28","author":"Hsiao","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1007\/s13311-012-0159-0_bib27","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(05)60398-4","article-title":"Delayed occurrence of Graves' disease after immune restoration with HAART","volume":"352","author":"Gilquin","year":"1998","journal-title":"Lancet"},{"key":"10.1007\/s13311-012-0159-0_bib28","first-page":"2052","article-title":"IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)","volume":"119","author":"Jones","year":"2009","journal-title":"J Clin Invest"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-012-0159-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-012-0159-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923016963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923016963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-012-0159-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:08:59Z","timestamp":1761808139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923016963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S1878747923016963"],"URL":"https:\/\/doi.org\/10.1007\/s13311-012-0159-0","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alemtuzumab Therapy for Multiple Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-012-0159-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}